*Salmonella enterica* serotype Choleraesuis usually causes invasive infection ([@R1]). When resistant *Salmonella* infection is encountered, fluoroquinolones or extended-spectrum cephalosporins are frequently used ([@R2]). Fluoroquinolone resistance has been common in this invasive serotype ([@R3]). Isolation of SC-B67, a strain of *S. enterica* ser. Choleraesuis that was resistant to ciprofloxacin and ceftriaxone (CIP^r^/CRO^r^), has exacerbated the problem ([@R4]). Ceftriaxone resistance in SC-B67 was attributed to a plasmid-mediated *bla*~CMY-2~, located on a specific IS*Ecp1*-*bla*~CMY-2~-*blc*-*sugE* structure ([@R4]). This conserved DNA fragment, subsequently named Tn*6092* ([@R5]), has been reported from different geographic areas and is widely distributed among various *Salmonella* serotypes and other Enterobacteriaceae ([@R6]).

The Study
=========

Since 1999, computerized records of bacterial culture results have been stored at Chang Gung Memorial Hospital, a 3,500-bed medical center in northern Taiwan. Periodic review of these records indicated a reverse trend in the prevalence of serogroups D (increase) and B (decrease) isolates during the past decade ([Figure 1](#F1){ref-type="fig"}, panel A). A significant decrease in the prevalence of *S. enterica* ser. Choleraesuis was also evident ([Figure 1](#F1){ref-type="fig"}, panel A). Nevertheless, in recent years, ceftriaxone resistance has increased from \<5% to \>10% in *S. enterica* ser. Choleraesuis and in serogroup B salmonellae ([Figure 1](#F1){ref-type="fig"}, panel B).

![Secular trends in annual numbers (A) and rates (B) of ceftriaxone resistance among various serogroups or serotype of nontyphoidal *Salmonella enterica* isolates in Chang Gung Memorial Hospital, 1999--2010.](10-1949-F1){#F1}

Since isolation of SC-B67 in 2002 ([@R4]), 10 CIP^r^/CRO^r^ *S. enterica* ser. Choleraesuis isolates have been recovered. All CIP^r^/CRO^r^ isolates were resistant to nalidixic acid and ciprofloxacin, but SC-B134 remained susceptible to ciprofloxacin ([Table 1](#T1){ref-type="table"}). PCR and sequencing with specific primers (Technical Appendix [Table 1](#T1){ref-type="table"}) revealed 3 identical amino acid changes in GyrA and ParC among all CIP^r^/CRO^r^ isolates except SC-B134 ([Table 1](#T1){ref-type="table"}). Reduced fluoroquinolone susceptibility of SC-B134 could be explained by the single amino acid change at codon 87 of GyrA. Amino acid changes were not found in GyrB or ParE.

###### Characteristics of the resistant Salmonella enterica isolates from 17 patients at Chang Gung Memorial Hospital, Taiwan\*

  Serotype and isolate (no. patients)   Year   Type of specimen   Susceptibility profile†   Puls‡   Plasmid profile, kb§          DNA--DNA hybridization¶         PCR sequencing\#                    
  ------------------------------------- ------ ------------------ ------------------------- ------- ----------------------------- ------------------------- ----- ------------------ -- ----- ---- -- -----
  Choleraesuis                                                                                                                                                                                        
  SC-B67                                2002   Blood              R/R/R                     C-1-a   50, **138**                   50                        50    138                   F     N       I
  SC-B104 (1)                           2003   Blood              R/R/R                     C-1-b   50, **150**                   50                        50    150                   F     N       I
  SC-B93 (2)                            2003   Blood              R/R/R                     C-1-b   50, **115**                   50                        50    50,115                F     N       I
  SC-B98 (3)                            2004   Blood              R/R/R                     C-1-c   50, **138**                   50                        50    138                   F     N       I
  NA (4)                                2004   Pus                R/R/R                     NA      NA                            NA                        NA    NA                    NA    NA      NA
  SC-B131 (5)                           2004   Blood              R/R/R                     C-1-d   50, **138**                   50                        50    138                   F     N       I
  SC-B132 (6)                           2004   Blood              R/R/R                     C-1-b   50, **150**                   50                        50    150                   F     N       I
  NA (7)                                2005   Pus                R/S/R                     NA      NA                            NA                        NA    NA                    NA    NA      NA
  SC-B134 (8)                           2007   Blood              R/S/R†                    C-1-e   40, 65, **[105]{.ul}**        65                        65    40                    Ser   N       Ser
  SC-B136 (9)                           2008   Blood              R/R/R                     C-2     115, **[138]{.ul}**           115                       115   115                   F     N       I
  NA (10)                               2009   Pus                R/S/R                     NA      NA                            NA                        NA    NA                    NA    NA      NA
  Typhimurium var. Copenhagen SB-5      2010   Feces              R/R/R                     B-1-a   7, **[125]{.ul}**, 180, 260   Neg                       Neg   Neg                   Ser   D       Ser
  Typhimurium                                                                                                                                                                                         
  SB-28                                 2010   Urine              R/R/S                     B-2     **[115]{.ul}**, 210           Neg                       Neg   Neg                   Ser   D       Ser
  SB-151                                2010   Feces              S/S/S                     B-1-b   **[85]{.ul}**                 Neg                       Neg   Neg                   Ser   D       Ser
  SB-193                                2010   Feces              R/R/S                     B-2     **[105]{.ul}**, 210           Neg                       Neg   Neg                   Ser   D       Ser
  Agona SB-105                          2010   Feces              R/S/S                     B-3     **[95]{.ul}**                 Neg                       Neg   Neg                   Ser   D       Ser
  Enteritidis SD-166                    2010   Feces              R/S/S                     D-1     45, 60, **[95]{.ul}**         60                        Neg   Neg                   Ser   D       Ser

\*Puls, pulsotype; R, resistant; F, phenylalanine; N, asparagine; I, isoleucine; NA, not available; S, susceptible; ser, serine; neg, negative reaction; var., variant; D, aspartic acid. †Antimicrobial drug susceptibility to chloramphenicol, trimethoprim/sulfamethoxazole, and quinolones. Results were the same for the 2 quinolones (nalidixic acid and ciprofloxacin) tested, except that SC-B134 was resistant to nalidixic acid and susceptible to ciprofloxacin. All isolates were resistant to ampicillin and ceftriaxone. ‡Pulsed-field gel electrophoresis; pulsotypes are expressed as serogroup-major type-subtype. §Plasmids harboring the *bla*~CMY-2~-carrying Tn*6092* element are shown in **boldface**. IncI1 plasmids are [underlined]{.ul}. Both are evidenced by DNA--DNA hybridization. ¶The size (kb) of the plasmid showing positive results in the respective DNA--DNA hybridization experiments is indicated. Rep_3, replicon of pSC138, the Tn*6092*-containing resistant plasmid of strain SC-B67. \#Amino acid changes compared with the quinolone resistance--determining regions of *gyrA* (codons 83 and 87) and *parC* (codon 80) in *S*. *enterica* serotype Typhimurium LT2. No mutation was found in *gyrB* and *parE*.

In terms of clinical features (Technical Appendix Table [2](#T2){ref-type="table"}), most patients with these infections were adults who had a wide spectrum of underlying diseases. Antimicrobial agents were prescribed for all patients, and extended-spectrum cephalosporins were used most frequently. Two patients died. Seven blood isolates from the 10 patients with CIP^r^/CRO^r^ *S. enterica* ser. Choleraesuis infections, together with the ceftriaxone-resistant isolates noted below, were investigated further. SC-B67 was used as a reference.

###### Characteristics of conjugative *bla*~CMY-2~-harboring IncI1 plasmids derived in this study and comparison of pMLST patterns with similar plasmids published previously\*

  IncI1 plasmid   *Salmonella enterica* serotype or *Escherichia coli*   Susceptibility profile†   Country   Year of isolation   pMLST‡   ST§   Clonal complex   Reference                          
  --------------- ------------------------------------------------------ ------------------------- --------- ------------------- -------- ----- ---------------- ----------- --- ---- ------------- ------------
  repI1           *ardA*                                                 *trbA*                    *sogS*    *pilL*                                                                                 
  pSC-B134        Choleraesuis                                           R/S/S                     Taiwan    2007                1        1     15               9           3   51   NA            This study
  pSC-B136        Choleraesuis                                           R/R/S                     Taiwan    2008                1        4     15               11          2   52   NA            This study
  pSB-5           Typhimurium variant Copenhagen                         R/R/R                     Taiwan    2010                2        1     15               11          2   53   NA            This study
  pSB28           Typhimurium                                            S/S/S                     Taiwan    2010                1        4     5                11          2   54   NA            This study
  pSB151          Typhimurium                                            S/S/S                     Taiwan    2010                4        5     15               11          3   55   NA            This study
  pSB193          Typhimurium                                            S/S/S                     Taiwan    2010                1        4     5                11          2   54   NA            This study
  pSB105          Agona                                                  R/S/S                     Taiwan    2010                2        1     15               11          3   56   NA            This study
  pSD166          Enteritidis                                            R/S/S                     Taiwan    2010                2        1     15               11          3   56   NA            This study
  398T            *E. coli*                                              NA                        Italy     2006                1        2     3                2           1   2    CC-2          ([@R12])
  05--1909        Heidelberg                                             NA                        Canada    2005                1        2     3                2           1   2    CC-2          ([@R13])
  1358T           Thompson                                               NA                        USA       1996                1        3     3                4           1   4    CC-12         ([@R12])
  DH-20406        Heidelberg                                             NA                        USA       2004                1        4     3                4           1   12   CC-12         ([@R14])
  06--3048        4,5,12:i:--                                            NA                        Canada    2006                1        4     3                4           1   12   CC-12         ([@R13])
  06--3539        Agona                                                  NA                        Canada    2006                1        4     3                4           1   12   CC-12         ([@R13])
  N07--0084       *E. coli*                                              NA                        Canada    2005                1        4     3                4           1   12   CC-12         ([@R13])
  05--2835        Heidelberg                                             NA                        Canada    2005                1        4     3                4           1   12   CC-12         ([@R13])
  06--3985        Litchfield                                             NA                        Canada    2006                1        4     3                4           1   12   CC-12         ([@R13])
  05--5567        Typhimurium                                            NA                        Canada    2005                1        4     3                4           1   12   CC-12         ([@R13])
  N06--523        *E. coli*                                              NA                        Canada    2006                1        4     3                2           1   18   CC-2/ CC-12   ([@R13])
  N06--0537       *E. coli*                                              NA                        Canada    2006                1        3     3                4           3   19   CC-12         ([@R13])
  05--6117        4,5,12:1:--                                            NA                        Canada    2006                1        1     3                9           1   20   NA            ([@R13])
  N07--0093       *E. coli*                                              NA                        Canada    2005                1        1     3                9           1   20   NA            ([@R13])
  06--0753        Heidelberg                                             NA                        Canada    2006                1        2     11               3           3   21   CC-5          ([@R13])
  N07--0079       *E. coli*                                              NA                        Canada    2005                1        6     3                4           1   22   CC-12         ([@R13])
  N07--0081       *E. coli*                                              NA                        Canada    2005                1        2     3                1           1   23   CC-2          ([@R13])

\*pMLST, plasmid multilocus sequence typing; ST, sequence type; R, resistant; S, susceptible; NA, not applicable. †Antimicrobial drug susceptibility to chloramphenicol, trimethoprim/sulfamethoxazole, and quinolones (nalidixic acid and ciprofloxacin). The transconjugants were also resistant to ampicillin and ceftriaxone. ‡pMLST results were compared to those published in the plasmid MLST website (<http://pubmlst.org/plasmid>). §STs were designated according to the different combinations of allele variants observed among the IncI1 plasmids.

During the first 6 months of 2010, a total of 6 cases of ceftriaxone-resistant *Salmonella* infection were found: serogroup B in 5 patients (*S*. *enterica* ser. Agona, n = 1; *S*. *enterica* ser. Typhimurium, n = 4, including 1 Copenhagen variant) and serogroup D (*S*. *enterica* ser. Enteritidis) in 1 patient ([Table 1](#T1){ref-type="table"}). All isolates were derived from fecal specimens of patients \<3 years of age, except *S*. *enterica* ser. Typhimurium SB-28, which was isolated from the urine of a 77-year-old patient. In contrast to *S. enterica* ser. Choleraesuis, these ceftriaxone-resistant isolates generally remained susceptible to fluoroquinolones ([Table 1](#T1){ref-type="table"}).

Pulsed-field gel electrophoresis performed as described showed close association among all *S*. *enterica* ser. Choleraesuis isolates, including SC-B67 ([Table 1](#T1){ref-type="table"}; [Figure 2](#F2){ref-type="fig"}, panel A) ([@R7]). Only strain SC-B136, recovered in 2008, demonstrated a relatively different pattern. Two pulsotypes, with minor differences, were found among the 4 *S. enterica* ser. Typhimurium isolates ([Table 1](#T1){ref-type="table"}).

![Analyses of *Salmonella* *enterica* serotype Choleraesuis isolates from Chang Gung Memorial Hospital, 1999--2010. A) Pulsed-field gel electrophoresis patterns. Lanes 1 and 10, DNA size markers demonstrated by a λ DNA concatemer standard and *S. enterica* ser. Braenderup H9812, respectively; lanes 2 to 9, *S*. *enterica* ser. Choleraesuis SC-B67, SC-B104, SC-B93, SC-B98, SC-B131, SC-B132, SC-B134, and SC-B136. B) Plasmid analysis and C) DNA--DNA hybridization. Probes for DNA--DNA hybridization of lanes 1--6, 7--12, and 13--16 were prepared from amplicons of *spvC*, Rep_3 replicon of pSC138 in SC-B67, and repI1, respectively; lanes 1 and 7, *S. enterica* ser. Choleraesuis OU7529 containing 2 plasmids of known sizes, 50 kb and 90 kb, was used as the size marker; lanes 2 and 8, SC-B67; lanes 3, 9, and 13, SC-B134; lanes 4, 10, and 14, SC-B136; lanes 5, 11, and 15, *Escherichia coli* J53/pSC-B134; lanes 6, 12, and 16, *E. coli* J53/pSC-B136.](10-1949-F2){#F2}

Ceftriaxone resistance was investigated by using PCR and sequencing as described ([@R6]). The specific *bla*~CMY-2~-carrying Tn*6092* was present in all isolates tested ([Table 1](#T1){ref-type="table"}). Tn*6092* was located within a *finQ* gene at a position identical to that in SC-B67. The only difference was in SC-B134; a 1,338-bp insertion sequence, IS*10*, was inserted 262 bp upstream of the *bla*~CMY-2~. No CTX-M and SHV genes were found in these isolates.

Using an alkaline lysis method ([@R8]), we found various numbers of plasmids among the isolates studied ([Table 1](#T1){ref-type="table"}). DNA--DNA hybridization indicated that Tn*6092* was located on large (85-kb to 150-kb) plasmids ([Table 1](#T1){ref-type="table"}) ([@R9]). An identical Rep_3 replicon was found in all CIP^r^/CRO^r^ *S*. *enterica* ser. Choleraesuis isolates studied ([@R5]). Similar to SC-B67, the Rep_3 replicon was located on the Tn*6092*-harboring resistance plasmid in the 5 resistant isolates recovered before 2004 ([Table 1](#T1){ref-type="table"}). However, in SC-B134, the Rep_3 replicon was found on the smaller 40-kb plasmid, and in SC-B136, the Rep_3 replicon was on the 115-kb large virulence plasmid that contained the *spvC* gene ([Table 1](#T1){ref-type="table"}; [Figure 2](#F2){ref-type="fig"}, panels B, C). Replicons FIIA and FIB were simultaneously present in all the *spvC*-containing virulence plasmids among the *S. enterica* ser. Choleraesuis isolates studied ([Table 1](#T1){ref-type="table"}). Virulence plasmids in the 2 recent isolates, SC-B134 and SC-B136, appeared larger than those in earlier isolates, including SC-B67 ([Table 1](#T1){ref-type="table"}; [Figure 2](#F2){ref-type="fig"}, panels B, C). The 2 bands demonstrated by the *spvC* probe in SC-B134 were from the same single virulence plasmid, as proven by hybridization experiments on *Bam*HI-digested plasmid DNA of SC-B134 (data not shown).

Replicon typing through a published multiplex PCR system revealed a replicon I1 from the Tn*6092*-harboring resistance plasmids in SC-B134 and SC-B136 ([Table 1](#T1){ref-type="table"}; [Figure 2](#F2){ref-type="fig"}, panel C) ([@R10]). Similarly, Tn*6092*-carrying plasmids among the other ceftriaxone-resistant salmonellae isolates all belonged to the IncI1 group ([Table 1](#T1){ref-type="table"}). Conjugation experiments using a filter mating method showed that all IncI1 resistant plasmids were self-transferrable ([@R11]). With azide-resistant *Escherichia coli* J53 and *S*. *enterica* ser. Typhimurium LBNP4417 as the recipients, the IncI1-resistant plasmids were confirmed to be self-transferrable.

Subtyping of the 8 conjugated IncI1 plasmids was achieved by using a recently described plasmid multilocus sequence typing (pMLST) method specifically set up for IncI1 plasmids ([@R12]). Six combinations of allele variants were obtained ([Table 2](#T2){ref-type="table"}). Because these pMLST patterns differed from those reported elsewhere, 6 new sequence types (STs) were designated ([Table 2](#T2){ref-type="table"}). Two major groups were further derived: ST54 (pSB28, pSB193) and ST52 (pSC-B136) that differed only in *trbA*, and ST56 (pSD166, PSB105) and ST53 (pSB5) that only differed in *pilL* ([Table 2](#T2){ref-type="table"}). pMLST patterns of representative *bla*~CMY-2~-carrying IncI1 plasmids published in recent years ([Table 2](#T2){ref-type="table"}) were derived from *E. coli* or various *Salmonella* serotypes in Europe or North America ([@R12]*--*[@R14]). Nine STs and 2 major clonal complexes, CC-2 and CC-12, were observed. pMLST patterns found in the present study differed from these STs by at least 3 alleles ([Table 2](#T2){ref-type="table"}).

Conclusions
===========

Resistance to ciprofloxacin and ceftriaxone remains high, indicating persistence of antimicrobial drug--resistant traits in *S. enterica* ser. Choleraesuis. The conserved genotypes found in the clinical isolates suggest a mode of clonal dissemination. However, plasmid analysis indicates that the location of the Tn*6092*-containing resistance element had shifted from the nonconjugative Rep_3 plasmids in early isolates to the self-transferable IncI1 plasmids in recent isolates. The emergence of such self-transferable resistance plasmids seems to provide an efficient way for *S. enterica* ser. Choleraesuis to spread its ceftriaxone resistance trait.

Because infections with nontyphoid salmonellae are rampant in Asia, emergence of a conjugative IncI1 resistance plasmid in ceftriaxone-resistant salmonellae from an Asian country is of public health concern. Presence of *bla*~CMY-2~-carrying IncI1 plasmids in a variety of *Salmonella* serotypes has been reported, but to our knowledge, not in *S. enterica* serotypes Enteritidis or Choleraesuis ([@R12]*--*[@R14]). IncI1 plasmids of the same or similar STs have been found in isolates of different bacterial species; with different resistance genes; or from different countries or sources, including human, animals, and the environment ([@R12]*--*[@R15]). Emergence of the IncI1 plasmid in Taiwan represents a need for continuous efforts to monitor and control its further spread.
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